Dr Lisa Holland
Contact information
Lisa Holland
PhD
Research Facilitator
Lisa is Research Facilitator for the Mexico City Prospective Study – a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
She joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2006 as a member of the Vascular Overviews Group. Lisa worked on the meta-analyses of clinical trials of statins (Cholesterol Treatment Trialists Collaboration), of non-steroidal anti-inflammatory drugs (Coxib and NSAID Trialists Collaboration), and of angiotension receptor blockers for the treatment of Marfan Syndrom.
Lisa Holland completed an undergraduate degree in Biochemistry with Microbiology at Lancaster University and a PhD in Molecular Microbiology at the University of Nottingham.
Recent publications
Kidney Function and Mortality in Mexico: Prospective Study of 130,000 Adults.
Journal article
Aguilar-Ramirez D. et al, (2026), Kidney Med, 8
Type 2 diabetes genetics in 125,000 admixed adults from Mexico City.
Preprint
Torres JM. et al, (2026)
Blood pressure, kidney function and kidney mortality in Mexico: prospective study of 130,000 adults
Journal article
EMBERSON J. et al, (2026), American Journal of Kidney Diseases
Polygenic prediction of coronary heart disease among 130 000 Mexican adults.
Journal article
Liu T. et al, (2026), Eur J Prev Cardiol, 33, 415 - 423
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Journal article
Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet, 407, 689 - 703